Search Results 11-20 of 20243 for Two-phase

  1. The Mayo Clinic Diet: A weight-loss program for life

    ... two-week phase. After that, you transition into the second phase, where you continue to lose 1 to 2 pounds (0.5 to 1 kilograms) a week until you reach your ...

  2. A Randomized, Open-label Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy after Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma - Mayo Clinic

    A Randomized, Open-label Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy after Rituximab Containing Chemotherapy ...

  3. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

    TP-0903 is shown to block cancer cell epithelial-to-mesenchymal transitions. AXL was identified as a potential therapeutic target in chronic lymphocytic ...

  4. Mayo Clinic Comprehensive Cancer Center — Research

    The study will be performed in two phases: Phase I will be performed for biologic validation of marker candidates from a discovery cohort and phase II will ...

  5. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy - Mayo Clinic

    The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure ...

  6. Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria - PHYOX 2 - Mayo Clinic

    Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous ...

  7. A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma - Mayo Clinic

    The purpose of this study is to determine the overall survival of patients treated with Vigil versus gemcitabine/docetaxel. Participation eligibility.

  8. A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Mayo Clinic

    cetuximab as single-agent (Arm 2) in RM HNSCC patients' naïve to cetuximab. Patients in scheme 1 will be randomized in a 2:1 ratio via IRT in two Phase II arms: ...

  9. A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer - Mayo Clinic

    A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients. Participation eligibility.

  10. Phase 2 Study with TTI-622 and TTI-621 in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) - Mayo Clinic

    About this study. The purpose of ths study is to find out more about the side effects of two new drug combinations for lymphoma, TTI-621 and pembrolizumab ...